

Sutter Health news and messages

- Home
- <u>Quality</u>
- Expanding Access
- <u>Community Benefit</u>
- Transformation
- <u>Research</u>
- <u>We're Awesome</u>
- <u>Affiliates »</u>
- <u>Cardiac</u>
- Community Benefit
- Innovation
- Memorial Hospital Foundation
- <u>Memorial Medical Center</u>
- Organ Donation
- Orthopedic Services
- People
- Sutter Health | Aetna
- <u>Sutter Roseville Medical Center</u>

Search this site Search this site...

Home » Quality » Cord Blood Stem Cell Study Shows Promise for Autism

Q

Helpful Links

- <u>About</u>
- Media Contacts
- <u>Affiliate News</u>
- <u>Annual Report</u>
- Facts at a Glance
- Financials

Browse By

Burlingame Modesto Oakland Palo Alto Sacramento San Francisco Santa Rosa More Cities

Archived News

All News 2017 All News 2016 All News 2015 All News 2014 All News 2013 More Archived News

Cord Blood Stem Cell Study Shows Promise for Autism

Posted on Feb 7, 2018 in Quality, Research, Uncategorized

Like 13 Tweet G+ SACRAMENTO, Calif. – A first-of-its-kind double-blinded, crossover study of children with autism who were treated with their own cord

blood showed the treatment to be safe and suggests improvement in socialization.



Michael Chez, M.D., of Sutter Neuroscience Institute.

The study, which was published Feb. 6 in the medical journal *Stem Cells Translational Medicine*, involved 30 children and was conducted by Michael Chez, M.D., the primary investigator who designed the study that was carried out through the Sutter Neuroscience Institute of Sacramento and the Sutter Institute for Medical Research, with research grant funding by Cord Blood Registry® (CBR®). It was the first randomized, double-blinded, placebo-controlled trial performed in the United States to assess the feasibility of treating autistic children by using their own newborn cord blood harvested from their banked umbilical cord. The study can be viewed <u>here</u>.

One of the most exciting outcomes of the study, said Dr. Chez, who is with Sutter Neuroscience Institute, involved successful treatment and blinding of parents and investigators, and safety and tolerability of the treatment in this autistic patient population. Trends toward improvements in areas such as socialization and language were observed.

"The Vineland Adaptive Behavior Scale for Socialization, one of the tests commonly used to measure real-world functional abilities, showed significant improvement after 12 weeks of cord blood treatment over placebo," Dr. Chez said. However, when correcting for possible statistical chance when looking at

many outcome variables, this observed significance no longer reached significance, probably due to variables such as only 30 patients in this pilot research study.

The study mirrored a recent non-blinded, open-label Duke University trial that showed similar Vineland Socialization score improvements while also demonstrating that the use of autologous cord blood is safe for the children through intravenous infusions.

Parents contacted about the study were pleased with the improvements they saw in their children.

Jennifer Lundberg of Orlando, Fla., said she knew almost immediately when Hayden received the cord blood infusion as opposed to the saline.

"We had been trying for more than four years to have him potty-trained, and within two weeks he started to self-potty. We never thought this was possible," she said. "He also now has this global understanding of language that he didn't have before. For example, I would ask him to open up the air-conditioning vents, and he all of a sudden knew what to do. He doesn't have the same outbursts that he used to have. It is truly amazing. If we could do it again, we definitely would do it again."

Another mother who asked not to be identified said her young son also improved. "We saw improvements in his overall development – in his language and social interaction," she said. "It definitely helped."

CBR has long been committed to supporting research on the use of cord blood to treat a variety of diseases from cerebral palsy and autism to hearing loss and Type I diabetes.

"The outcome of Dr. Chez's study, in addition to other recent research advances looking at the use of cord blood for children with autism, are encouraging," said Heather Brown, vice president of scientific and medical affairs, CBR. "As researchers continue to explore cord blood's role in regenerative medicine, CBR remains dedicated to investing in clinical trials to better understand this potential and investigating ways we can increase cord blood's utility."

Sutter Neuroscience Institute and Sutter Institute for Medical Research are affiliates of Sutter Health, Northern California's largest health provider.

###

Opens in new Window	Opens in new Window	Opens in new Window
Opens in new Window	Opens in new Window	Opens in new Window

Posted by <u>Gary Zavoral</u> on Feb 7, 2018 in <u>Quality</u>, <u>Research</u>, <u>Uncategorized</u> | Comments Off on Cord Blood Stem Cell Study Shows Promise for Autism

If you liked this article, you may also like:

- <u>Sutter Children's Center, Sacramento Volunteer Earns Prestigious Community Service Award</u>
- <u>Study: Ibuprofen Safe for Infants Under 6 Months</u>
- Sutter Health invests \$2.3 Million to Address Homelessness in the City of Sacramento
- <u>Sutter ICUs Receive Beacon Awards for Critical-Care Excellence</u>
- <u>App Created to Educate Clinicians, Public about Chest-Wall Deformities</u>

Connect with Us



About

The Sutter Health News Room provides the latest health care news articles, resources and more about health care quality, medical technology, hospital construction and more across Northern California.

RSS and E-Subscribe

Enter your email address:	
Subscribe Delivered by FeedBurner	

Hospitals, Services and Locations

• Find Sutter Health Hospitals, Medical Groups and Specialty Care

Policies

- Privacy and Disclosure
- Nondiscrimination Policy

Contact Sutter Health

<u>Contact Us</u>